We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | LSE:0RN3 | London | Ordinary Share | JP3463000004 | TAKEDA PHARMACEUTICAL ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.35 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.05T | 317.02B | 200.3525 | 0.13 | 40.78B |
From Apr 2019 to Apr 2024
TIDM0RN3
FORM 8.3 Amendment to Sales
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
Hot Features
Premium
(a) Full name of discloser: Barclays PLC.
(b) Owner or controller of
interest and short
positions disclosed, if
different from 1(a):
(c) Name of offeror/offeree TAKEDA PHARMACEUTICAL CO LTD
in relation to whose
relevant securities this form relates:
(d) If an exempt fund manager
connected with an
offeror/offeree, state this
and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 07 January 2019
(f) In addition to the company in 1(c) YES:
above, is the discloser making
disclosures in respect of any SHIRE PLC
other party to the offer?
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant Ordinary NPV
security:
Interests Short Positions
Number (%) Number (%)
(1) Relevant
securities
owned
and/or 11,639,618 1.48% 18,916,042 2.38%
controlled:
(2) Cash-settled
derivatives:
8,788,961 1.11% 1,675,035 0.21%
(3) Stock-settled
derivatives
(including
options)
and agreements 514,600 0.06% 514,600 0.06%
to
purchase/sell:
TOTAL: 20,943,179 2.65% 21,105,677 2.66%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit security securities ADR Purchase 19 18.6000 USD ADR Purchase 47 18.5600 USD ADR Purchase 100 18.4900 USD ADR Purchase 100 18.6250 USD ADR Purchase 300 18.5500 USD ADR Purchase 1,100 18.5845 USD ADR Purchase 2,400 18.5725 USD ADR Purchase 6,100 18.5111 USD ADR Purchase 6,600 18.5657 USD ADR Purchase 68,400 18.5630 USD ADR Purchase 74,900 18.5633 USD ADR Purchase 170,800 18.5662 USD ADR Sale 19 18.6000 USD ADR Sale 47 18.5600 USD ADR Sale 100 18.6250 USD ADR Sale 100 18.4750 USD ADR Sale 100 18.5250 USD ADR Sale 200 18.5850 USD ADR Sale 246 18.6100 USD ADR Sale 300 18.5050 USD ADR Sale 300 18.5700 USD ADR Sale 400 18.5175 USD ADR Sale 600 18.5083 USD ADR Sale 800 18.5112 USD ADR Sale 1,200 18.5095 USD ADR Sale 1,300 18.5115 USD ADR Sale 1,300 18.5146 USD ADR Sale 3,900 18.5720 USD ADR Sale 4,200 18.6650 USD ADR Sale 4,500 18.5550 USD ADR Sale 4,703 18.5552 USD ADR Sale 5,100 18.5452 USD ADR Sale 7,200 18.5470 USD ADR Sale 8,298 18.5682 USD ADR Sale 9,100 18.5728 USD ADR Sale 11,714 18.5457 USD ADR Sale 19,645 18.5660 USD ADR Sale 19,883 18.5673 USD ADR Sale 39,500 18.5521 USD ADR Sale 47,748 18.5693 USD ADR Sale 65,900 18.5621 USD ADR Sale 77,009 18.5756 USD Ordinary NPV Purchase 800 3,978.6875 JPY Ordinary NPV Purchase 1,000 3,951.1000 JPY Ordinary NPV Purchase 1,000 3,978.4000 JPY Ordinary NPV Purchase 1,700 3,987.4058 JPY Ordinary NPV Purchase 1,700 3,990.2764 JPY Ordinary NPV Purchase 1,900 3,992.5789 JPY Ordinary NPV Purchase 2,400 3,966.4166 JPY Ordinary NPV Purchase 3,100 3,991.0000 JPY Ordinary NPV Purchase 3,100 3,987.1871 JPY Ordinary NPV Purchase 3,500 3,991.1714 JPY Ordinary NPV Purchase 4,300 3,977.2790 JPY Ordinary NPV Purchase 4,500 3,963.4777 JPY Ordinary NPV Purchase 4,600 3,941.3260 JPY Ordinary NPV Purchase 4,800 4,035.7500 JPY Ordinary NPV Purchase 5,800 3,984.0000 JPY Ordinary NPV Purchase 7,700 3,978.6883 JPY Ordinary NPV Purchase 8,700 3,970.2701 JPY Ordinary NPV Purchase 9,700 3,915.8762 JPY Ordinary NPV Purchase 9,900 3,987.6666 JPY Ordinary NPV Purchase 11,500 3,986.7834 JPY Ordinary NPV Purchase 11,900 3,971.6890 JPY Ordinary NPV Purchase 12,900 3,979.8062 JPY Ordinary NPV Purchase 13,000 3,975.1538 JPY Ordinary NPV Purchase 17,600 3,981.8636 JPY Ordinary NPV Purchase 19,400 3,978.5670 JPY Ordinary NPV Purchase 30,000 3,981.0266 JPY Ordinary NPV Purchase 31,200 3,978.2115 JPY Ordinary NPV Purchase 47,300 3,980.2304 JPY Ordinary NPV Purchase 98,200 3,990.7841 JPY Ordinary NPV Purchase 190,000 3,954.4900 JPY Ordinary NPV Purchase 421,200 3,979.5439 JPY Ordinary NPV Purchase 456,700 3,980.0102 JPY Ordinary NPV Purchase 859,100 3,981.3206 JPY Ordinary NPV Purchase 866,900 3,980.0862 JPY Ordinary NPV Sale 400 3,966.0000 JPY Ordinary NPV Sale 400 3,998.7500 JPY Ordinary NPV Sale 1,000 3,945.8000 JPY Ordinary NPV Sale 1,000 3,951.1000 JPY Ordinary NPV Sale 1,000 4,006.9000 JPY Ordinary NPV Sale 1,600 3,991.6000 JPY Ordinary NPV Sale 1,700 3,990.2764 JPY Ordinary NPV Sale 2,000 4,034.6500 JPY Ordinary NPV Sale 2,400 3,966.4166 JPY Ordinary NPV Sale 2,800 3,989.5357 JPY Ordinary NPV Sale 4,100 3,981.4097 JPY Ordinary NPV Sale 4,300 3,977.2790 JPY Ordinary NPV Sale 6,700 3,966.3432 JPY Ordinary NPV Sale 8,400 4,014.0476 JPY Ordinary NPV Sale 8,700 3,970.2701 JPY Ordinary NPV Sale 8,700 3,974.0000 JPY Ordinary NPV Sale 11,500 3,986.7834 JPY Ordinary NPV Sale 11,700 3,971.4615 JPY Ordinary NPV Sale 13,000 4,080.0000 JPY Ordinary NPV Sale 100,000 3,975.4300 JPY Ordinary NPV Sale 421,200 3,978.9399 JPY Ordinary NPV Sale 846,100 3,979.8045 JPY Ordinary NPV Sale 869,300 3,980.0473 JPY Ordinary NPV Sale 1,033,600 3,978.4521 JPY
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 1,600 4,057.6300 JPY Ordinary NPV CFD Long 150,000 3,985.9913 JPY Ordinary NPV SWAP Short 2,800 3,969.6778 JPY Ordinary NPV CFD Short 8,300 3,993.8209 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number Exercise price Type Expiry date Option money
relevant descriptione.g. purchasing, of securities per unit e.g. American, paid/
security call selling, to European etc. received
option varying etc. which option per unit
relates
(ii) Exercise
Class of relevant Product Exercising/ Number Exercise price
security description exercised of securities per unit
e.g. call against
option
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None
(c) Attachments
Is a Supplemental Form 8 (Open YES Positions) attached? Date of disclosure: 9 Jan 2019 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Identity of the person whose Barclays PLC. positions/dealings are being disclosed: Name of offeror/offeree TAKEDA PHARMACEUTICAL CO LTD in relation to whose relevant securities this from relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class Product Writing, Number Exercise Type Expiry
of description purchasing, of price date
relevant selling, securities per unit
security varying etc to which
option
relates
Ordinary Call Purchased 150,000 3889.0000 American 11 Jun 2021
NPV Options
Ordinary Call Written -114,000 4750.0200 European 14 May 2019
NPV Options
Ordinary Call Written -104,700 5065.8300 European 17 Apr 2019
NPV Options
Ordinary Call Written -75,900 4286.5200 European 6 Sep 2019
NPV Options
Ordinary Call Written -70,000 4598.0000 European 14 Jun 2019
NPV Options
Ordinary Put Purchased -150,000 3889.0000 American 11 Jun 2021
NPV Options
Ordinary Put Written 70,000 4598.0000 European 14 Jun 2019
NPV Options
Ordinary Put Written 75,900 4286.5200 European 6 Sep 2019
NPV Options
Ordinary Put Written 104,700 5065.8300 European 17 Apr 2019
NPV Options
Ordinary Put Written 114,000 4750.0200 European 14 May 2019
NPV Options
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005528/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
January 09, 2019 09:49 ET (14:49 GMT)
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
